Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20219039 | 0.75 | TSHR (0.76) | TSHRFABP4KDM4ESMN1; SMN2HPGD | |
| SCHEMBL31023418 | 0.73 | TSHR (0.73) | TSHRFABP4KDM4ESMN1; SMN2HPGD | |
| SCHEMBL4002460 | 0.73 | TSHR (0.73) | TSHRFABP4KDM4ESMN1; SMN2HPGD | |
| SCHEMBL5025301 | 0.73 | TSHR (0.53) | TSHRFABP4KDM4ESMN1; SMN2HPGD | |
| SCHEMBL27833985 | 0.72 | TSHR (0.71) | TSHRFABP4KDM4ESMN1; SMN2HPGD | |
| SCHEMBL15302068 | 0.72 | TSHR (1.00) | L3MBTL1TSHRFABP4KDM4ESMN1; SMN2 | |
| SCHEMBL7933287 | 0.72 | TSHR (0.71) | TSHRFABP4KDM4ESMN1; SMN2HPGD | |
| SCHEMBL10032004 | 0.72 | TSHR (0.71) | L3MBTL1TSHRFABP4KDM4EHPGD | |
| SCHEMBL23540894 | 0.72 | TSHR (0.66) | L3MBTL1TSHRFABP4KDM4ESMN1; SMN2 | |
| SCHEMBL9775876 | 0.71 | TSHR (0.69) | TSHRFABP4KDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446120-B2 | Peptidomimetic modulators of cell adhesion | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-11-04 | — | — | US | disclosed |
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | US | disclosed |
| US-7268115-B2 | Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery | ADHEREX TECHNOLOGIES, INC. (CA) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | BMP1, BMP2, BMP4 | L3MBTL1 2651/4885GAA 3737/4885TSHR 3913/4885 |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | CDH1, EPCAM, VCAM1 | L3MBTL1 1410/4885GAA 4183/4885TSHR 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.